Feedback PLC Result of Annual General Meeting - Amendment (5643E)

TIDMFDBK

RNS Number : 5643E

Feedback PLC

06 November 2020

The following amendments have been made to the 'Result of Annual General Meeting' announcement released on 5 November 2020 at 1.23 pm under RNS No 4187E.

The 'Total Votes Cast' column in the table below has been updated to show the correct figures. All other details remain unchanged. The full amended text is shown below.

Feedback plc

Result of Annual General Meeting - Amendment

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that at its annual general meeting held earlier today, all resolutions were duly passed on a poll. The proxy voting results of the resolutions are included below.

 
Resolutions               Votes For*   % of     Votes       % of votes  Votes        Total votes 
                                        votes    Against     cast**      Withheld**   cast** 
                                        cast** 
 
1. To receive 
 and adopt the 
 annual report 
 and accounts for 
 the year ended 
 31 May 2020              504,134,927  100.00%  -           0.00%       22,000       504,134,927 
 
2. To elect Adam 
 Denning as a director    504,152,622  100.00%  3,305       0.00%       1,000        504,155,927 
 
3. To elect Philipp 
 Prince as a director     479,902,622  95.19%   24,253,305  4.81%       1,000        504,155,927 
 
4. To re-elect 
 Simon Sturge as 
 a director               504,152,486  100.00%  3,441       0.00%       1,000        504,155,927 
 
5. To appoint 
 Price Bailey LLP 
 as auditors of 
 the Company              504,118,963  99.99%   36,964      0.01%       1,000        504,155,927 
 
6. To authorise 
 the directors 
 to allot relevant 
 securities equivalent 
 to up to two thirds 
 of the Company's 
 issued share capital, 
 subject to certain 
 conditions               504,027,372  100.00%  3,305       0.00%       126,250      504,030,677 
 
7. To authorise 
 the directors 
 to allot relevant 
 securities equivalent 
 to up to 10 per 
 cent. of the Company's 
 issued share capital 
 on a non-pre-emptive 
 basis subject 
 to certain conditions    478,945,731  95.01%   25,135,091  4.99%       76,205       504,080,822 
 

Notes:

* "Votes For" include votes giving the Chairman discretion.

** "Votes Withheld" are not votes in law and do not count in the number of votes counted for or against a resolution, or towards the total votes cast.

-Ends-

Enquiries:

 
Feedback plc                         [phone] 
 Tom Oakley, CEO                      [e-mail] 
 Lindsay Melvin, CFO 
 
Allenby Capital Limited (Nominated 
 Adviser) 
 David Worlidge / Asha Chotai        [phone] 
 
Peterhouse Capital Limited (Joint 
 Broker) 
 Lucy Williams / Duncan Vasey        [phone] 
 
Stanford Capital Partners Limited 
 (Joint Broker) 
 Patrick Claridge / John Howes       [phone] 
 
Walbrook PR Ltd                      Tel: [phone] or [e-mail] 
Paul McManus/Nick Rome/Nicholas      07980 541 893 or 07748 325 236 or 
 Johnson                              07884 664 686 
 

Notes to Editors

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGGZMGMKVGGGZM

(END) Dow Jones Newswires

November 06, 2020 13:41 ET (18:41 GMT)